Recent Updates
Recently added Catalysts

Filgrastim-SD/01

Phase 2

Non-small Cell Lung Cancer | Small molecule | Oncology |Amgen Inc.|Last Updated: Dec 27, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Clinical trial landscape

Filgrastim-SD/01 · 1 trial · 1 indication

Phase 2 1
NCT00050674Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer
COMPLETED40 Analytics
PHASE2COMPLETED
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Non-small Cell Lung Cancer
NCT0005067440
Unlock trial analytics

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Filgrastim-SD/01EXPERIMENTAL6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion

Interventions

NameTypeDescription
Filgrastim-SD/01DRUG6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

* Histologically or cytologically documented non-small cell lung cancer * Subjects must have stage IV or IIIB NSCLC * 0-1 prior treatment regimens of chemotherapy * Subjects must have bi-dimensionally measurable disease or evaluable disease by physical exam or radiological studies * Age \> 18 years ...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Non-Small Cell Lung Cancer 387 trials

Top 20 of 83 competitors

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK24PHASE3Pembrolizumab, Olaparib, Etoposide, Carboplatin, Cisplatin
AstraZeneca PLCAZN62PHASE3Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin
Revolution Medicines, Inc.RVMD8PHASE3daraxonrasib, docetaxel
Eli Lilly and CompanyLLY18PHASE3Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
AbbVie, Inc.ABBV10PHASE3Telisotuzumab Vedotin, Docetaxel
Bristol-Myers Squibb CompanyBMY18PHASE3Repotrectinib, Crizotinib
BioNTech SE Sponsored ADRBNTX7PHASE3Gotistobart, Docetaxel
Gilead Sciences, Inc.GILD4PHASE3Sacituzumab Govitecan-hziy, Docetaxel
Pfizer Inc.PFE16PHASE3Lorlatinib, Crizotinib
Johnson & JohnsonJNJ17PHASE3Lazertinib, Amivantamab, Pemetrexed, Carboplatin
ArriVent BioPharma, Inc.AVBP9PHASE3Firmonertinib
Amgen Inc.AMGN4PHASE3ABP 234, Pembrolizumab
Novartis AG Sponsored ADRNVS9PHASE3JDQ443, docetaxel
GSK plc Sponsored ADRGSK3PHASE3Dostarlimab, Belrestotug, Pembrolizumab
Summit Therapeutics IncSMMT2PHASE3Ivonescimab, Pembrolizumab
Nuvation Bio, Inc. Class ANUVB4PHASE3Taletrectinib, Crizotinib
Genmab A/S Sponsored ADRGMAB4PHASE3Acasunlimab, Pembrolizumab, Docetaxel
Regeneron Pharmaceuticals, Inc.REGN6PHASE2Cemiplimab, Platinum-based chemotherapy, REGN7075
BeOne Medicines Ltd. Sponsored ADRONC6PHASE3Tislelizumab, Cisplatin, Paclitaxel, Pemetrexed Disodium, Carboplatin
BeyondSpring Inc.BYSI1PHASE3Plinabulin, Docetaxel
Unlock Competitive Intelligence